Changes in oxidative stress haemostatic parameters during the thrombolytic treatment of pulmonary embolism;Az oxidatív stressz és haemostasis paramétereinek változása életveszélyes tüdoembólia thrombolyticus kezelése során

Orvosi Hetilap

Volumn 149, Issue 20, 2008, Pages 935-948

  Muhl, Diana ^a,b  

^a UNIVERSITY OF PÉCS   (Hungary)

^b NONE   (Hungary)

Author keywords

Leukocyte activation; Oxidative stress; Platelet aggregation; Pulmonary embolism; Thrombolysis

Indexed keywords

ADENOSINE DIPHOSPHATE; ADRENALIN; ALTEPLASE; BIOLOGICAL MARKER; CD18 ANTIGEN; CD97 ANTIGEN; COLLAGEN; D DIMER; FIBRINOGEN; GLUTATHIONE; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MALONALDEHYDE; MYELOPEROXIDASE; REACTIVE OXYGEN METABOLITE; STREPTOKINASE; SUPEROXIDE DISMUTASE;

ACUTE DISEASE; ANTIGEN EXPRESSION; ARTICLE; BLEEDING; BLOOD CLOT LYSIS; CHEMOLUMINESCENCE; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; EMBOLISM; ENZYME ACTIVITY; FIBRINOGEN BLOOD LEVEL; FIBRINOLYTIC THERAPY; FLOW CYTOMETRY; HEMOSTASIS; HUMAN; LEUKOCYTE ACTIVATION; LEUKOCYTE COUNT; LEUKOCYTE FUNCTION; LUNG EMBOLISM; LUNG PERFUSION; OXIDATIVE STRESS; REPERFUSION; THROMBOCYTE AGGREGATION;

EID: 44949133173     PISSN: 00306002     EISSN: 17886120     Source Type: Journal    
DOI: 10.1556/OH.2008.28356     Document Type: Article

References (44)

1. Goldhaber, S. Z., Visani, L., De Rosa, M.: Acute pulmonary embolism: clinical outcomes in the International Cooperation Pulmonary Embolism Registery (ICOPER). Lancet, 1999, 353, 1386-1389.
2. Van Beek, E. J. R., Ten Cate, J. W.: The diagnosis of venous thromboembolism: an overview. In: Hull, R. D., Raskob, G. E., Pineo, G. F. (szerk.): Venous Thromboembolism: an evidencebased atlas. Armonk, Futura Publishing Co., 1996, 93-99.
3. Sárosi I.: Pulmonalis embolia. Kardiológia 2000, Melania 2000, 429-436.
4. Stein, P. D., Henry, J. W.: Prevalence of acut pulmonary embolism among patiens in a general hospital and autopsy. Chest, 1995, 108, 78-81.
5. Kline, J., Hernandez-Nino, J., Newgard, C. D. és mtsai: Use of pulse oximetry to predict in-hospital complications in normotensive patients with pulmonary embolism. Am. J. Med, 2003, 115, 203-208.
6. Janata, K., Holzer, M., Domanovits, H. és mtsai: Mortality of patients with pulmonary embolism. Wien Klin. Wochenschr., 2002, 114, 766-772.
7. Meneveau, N., Ming, L. P., Séronde M. F. és mtsai: In hospital and long-term outcome after sub-massive and massive pulmonary embolism submitted to thrombolytic therapy. Eur. Heart J., 2003, 24, 1447-1454.
8. Büchner, S., Pfeiffer, B., Hachenberg, T.: Lungenembolie (CME 1/2/2005). Anasth. Intensivmed., 2005, 46, 9-22.
9. Martin, M.: Semiquantitative Plasminogenbestimmung mit Hilfe des Thrombelastographen. Eine Methode zur Kontrolle der Streptokinase-Behandlung. Thromb. Diath. Haemorrh., 1969, 22, 121.
10. Martin, M., Fiebach, O.: Short-term ultrahigh streptokinase treatment of chronic arterial occlusions and acute deep vein thromboses. Semin. Thromb. Hemost., 1991, 17, 21-37.
11. Moser, M., Nordt, T., Peter, K. és mtsai: Platelet function during and after thrombolytic therapy for acut myocardial infarction with reteplase, alteplase, or streptokinase. Circulation, 1999, 100, 1858-1864.
12. Gurbel, P. A., Serebruany, V. L., Shustov, A. R. és mtsai: Effect of reteplase and alteplase on platelet aggregation and major receptor expression during the first 24 hours of acute myocardial infarction treatment. GUSTO-III Investigators. J. Am. Coll. Cardiol., 1998, 31, 1466-1473.
13. Korbut, R., Gryglewski, R. J.: Platelets in fibrinolytic system. J. Physiol. Pharmacol., 1995, 46, 409-418.
14. Agnelli, G., Parise, P.: Bolus thrombolysis in venous thromboembolism. Chest, 1992, 101, 172-182.
15. Ryrfeldt, A., Bannenberg, G., Moldeus, P.: Free radicals and lung disease. Brit. Med. Bull., 1993, 49, 588-603.
16. Verma, S., Fedak, P., Weisel, R. és mtsai: Fundamentals of reperfusion injury for the clinical cardiologist. Circulation, 2002, 105, 2332-2336.
17. Souza-Costa, D. C., Zerbini, T., Metzger, I. F. és mtsai: L-Arginine attenuates acute pulmonary embolism-induced oxidative stress and pulmonary hypertension. Nitric Oxide, 2005, 12, 9-14.
18. Mühl, D., Füredi, R., Cristofari, J. és mtsai: Evaluation of oxidative stress in the thrombolysis of pulmonary embolism. J. Thromb. Thrombolys., 2006, 22, 221-228.
19. Ohakawa, H. N., Okishi, N., Yagi, K.: Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal. Biochem., 1979, 95, 351-358.
20. Sedlak, J., Lindsay, R. H.: Estimation of total protein-bound and non-protein sulphydryl groups in tissue with Ellman's reagent. Anal. Biochem., 1968, 25, 192-205.
21. Misra, H. P., Fridovich, I.: The role of superoxide anion in the antioxidation of epinephrine and a simple assay for superoxide dismutase. J. Biol. Chem., 1972, 27, 3170-3175.
22. Gasz B., Benko L., Jancsó G. és mtsai: Gyulladásos válaszreakciók monitorozása extracorporalis keringésben, illetve anélkül végzett koronária revascularizációt követoen. Cardiol. Hung., 2004, 34, 102-108.
23. Le Gal, G., Bounameaux, H.: Diagnosing pulmonary embolism: running after the decreasing prevalence of cases among suspected patients. J. Thromb. Haemost., 2004, 2, 1244-1246.
24. Yoshida, S., Kohro, S., Yamakage, M. és mtsai: A case of suspected pulmonary thrombosis in a patient with reactive thrombocytemia who underwent liver subsegment ectomy. Masui, 2003, 52, 1320-1322.
25. Lee, C., Ferguson, C.: Best evidence topic report. Aspirin in the treatment of acute pulmonary embolism. Emerg. Med. J., 2005, 22, 365.
26. Hoven, M. M., Snoep, J. D., Tamsma, J. T. és mtsai: Aspirin in the prevention and treatment of venous thromboembolism. J. Thromb. Haemost., 2006, 4, 1470-1475.
27. Baz, R., Li, L., Kottke Marchant, K. és mtsai: The role of aspirin in the prevention of thrombotic complications of thalidomide and antracycline-based chemotherapy for multiple myeloma. Mayo Clin. Proc., 2005, 80, 1549-1551.
28. Maillerdet, L., Cohen, A. T.: Aspirin in the prevention and treatment of venous thromboembolism: a rebuttal. J. Thromb. Haemost., 2007, 5, 212-214.
29. British Thoracic Society guidelines for managements of suspected acute pulmonary embolism. British Thoracic Society Standards of Care Committee Pulmonary Embolism Guideline Development Group. Thorax, 2003, 58, 470-484.
30. Liu, P., Meneveau, N., Schiele, F. és mtsai: Predictors of longterm clinical outcome of patients with acute massive pulmonary embolism after thrombolytic therapy. Chinese Med. J. (Engl.), 2002, 116, 503-509.
31. Wan, S., Quinlan, D. J., Agnelli, G. és mtsai: Thrombolysis compared with heparin for the initial treatment of pulmonary embolism. A meta-analysis of the randomized controlled trials. Circulation, 2004, 110, 744-749.
32. Weltermann, A., Eichinger, S., Bialonczyk, C. és mtsai: The risk of recurrent venous thromboembolism among patients with high factos IX levels. J. Thromb. Haemost., 2002, 1, 28-32.
33. Gurbel, P. A., Haves, K., Bliden, K. P. és mtsai: The platelet-related effects of tenetecteplase versus alteplase versus reteplase. Blood Coagul. Fibrin., 2005, 16, 1-7.
34. Serebruany, V. L., Malini, A. I., Callahan, K. P. és mtsai: Effect of tenetecteplase versus alteplase on platelets during the first 3 hours of treatment for acute myocardial infarction: the Assessment of the Safety and Efficacy of a New Thrombolytic Agent (ASSENT-2) platelet substudy. Am. Heart J., 2003, 145, 636-642
35. Alt, E., Amann-Vesti, B. R., Mabl, C. és mtsai: Platelet aggregation and blood rheology in severe septic shock: relation to the Sepsis related Organ Failure Assessment (SOFA) score. Clin. Hemorheol. Micro., 2004, 30, 107-115.
36. Mühl D., Füredi R., Gecse K. és mtsai: The time course of platelet aggregation during thrombolytic treatment of massive pulmonary embolism. Blood Coagul. Fibrin., 2007, 18, 661-667.
37. Smulders, Y. M.: Pathophysiology and treatment of haemodynamic instability in acute pulmonary embolism: the pivotal role of pulmonary vasoconstriction. Cardiovasc. Res., 2000, 48, 23-33.
38. Wagner, J. G., Roth, R. A.: Neutrophil migration mechanisms, with an emphasis on the pulmonary vasculature. Pharmacol. Rev., 2000, 52, 349-374.
39. Albelda, S. M., Smith, C. W., Ward, P. A.: Adhesion molecules and inflammatory injury. FASEB J., 1994, 8, 504-512.
40. Shimizu, Y., Nagaya, N., Satoh, T. és mtsai: Serum uric acid level increases in proportion to the severity of pulmonary thromboembolism. Circ. J., 2002, 66, 571-575.
41. Dikshit, M., Kumari, R., Srimal, R. C.: Effect of pulmonary thromboembolism on circulating neutrophils in mice. Thromb. Res., 1992, 66, 133-139.
42. Brzostowski, J. A., Kimmel, A. R.: Signaling at zero G: G-protein independent functions for 7-TM receptors. Trends Biochem. Sci., 2001, 26, 291-297.
43. Wagner, J. G., Roth, R. A.: Neutrophil migration mechanisms, with an emphasis on the pulmonary vasculature. Pharmacol. Rev., 2000, 52, 349-374.
44. Kerner, T., Ahlers, O., Reschreiter, H. és mtsai: Adhesion molecules in different treatments of acute myocardial infarction. Crit. Care, 2001, 5, 145-150.